Thyroid Cancer Detections Due to More Screenings With GLP-1s

New research, with the caveat of a relatively short follow-up, adds to encouraging data showing an overall low risk of the development of thyroid cancer associated with glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment. However, a notably increased rate of thyroid cancer detections limited only to the first year after drug initiation — but … Read more

GLP-1s Show No Increased Risk for Thyroid Cancer

In the largest study of its kind involving a diabetic population, the use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs shows no significantly increased risk for thyroid cancer, with the important caveat of the study’s relatively short follow-up period. “In this large multisite study utilizing data from 6 population-based databases, we found no … Read more